• Growth and capex: Sai Life Sciences expects 15–20% growth over the next few years following nearly 30% growth last year, while increasing capex to ₹1,100–1,300 crore this year from ₹630 crore last year and ₹250 crore two years ago.
• China+1 momentum: The US Department of Defense listing Wuxi AppTec serves as an additional catalyst for the ongoing shift toward Indian CDMOs, with large pharma clients actively reallocating supply to preferred vendors.
• Execution standards: The risk of trend reversal remains low given India's small share of Asian outsourcing, though CDMOs must navigate strict pharma capability standards where Sai Life Sciences currently serves 19 of the top 25 global pharma companies.
• GLP-1 opportunity: Large pharma companies are preparing GLP-1 drug launches across various clinical stages, positioning existing Indian CDMO partners to capture pipeline demand and scale capacity similarly to the 2005 generics boom.